06.05.2011 18:03:00

Cegedim Relationship Management Presents on Co-Pay Program ROI Methodologies at PMSA Conference

The OPUS Health division of Cegedim Relationship Management conducted a presentation entitled Best Practices in ROI Methodologies in Analyzing the Effectiveness of Patient Co-pay Savings Cards at the 2011 Annual Pharmaceutical Management Science Association (PMSA) Conference in Miami, Florida. OPUS Health’s Marketing Analytics Group is the only on-staff analytics group within the co-pay savings card supplier market to have ever received the prestigious invitation to present at a PMSA conference.

The presentation was an empirical case study using historical data from two different patient co-pay card programs using anonymous longitudinal patient-level data as well as prescriber-level data. The study compared two different tests versus control return on investment (ROI) analysis methodologies, their outcomes, and their ability to address the effectiveness of co-pay savings cards as a brand marketing tactic. The presentation was delivered by Cynthia Elkins, Senior Management Science Analyst, Alina Bichkovskaja, Client Services Technical Manager and Lynn Day, Senior Director, Marketing Analytics, all of Cegedim Relationship Management’s OPUS Health Division.

"In recent years, patient co-pay savings card programs have risen in prominence as a pharmaceutical marketing and sales tool because they give direct benefits to patients and are thought to increase new patient starts by overcoming economic barriers,” explained Mark Calabrese, Vice President and General Manager of OPUS Health for Cegedim Relationship Management. "It’s critical that these programs are subject to rigorous ROI analyses to be compared to other tools in the arsenal of pharma sales and marketing promotion. We have conducted many such analyses across various co-pay benefit designs and in almost every therapeutic category on behalf of our varied client base.”

OPUS Health is a provider of pharmaceutical marketing solutions including the IntelliScript Co-Pay Program and Marketing and Sales Analytics Services. "We are the industry experts in the use of anonymous longitudinal patient-level data,” said Mr. Calabrese. "Our IntelliScript program analyses provide our clients with actionable patient and prescriber marketing insights, giving them an advantage over their competition.”

The PMSA 2011 Annual Conference was held this week at the Loews Miami Beach Hotel. The poster session, during which Cegedim Relationship Management presented, is a perennial conference tradition which gives attendees the opportunity to interact face-to-face with presenters of analytic concepts.

About Cegedim Relationship Management: Cegedim Relationship Management is the Life Sciences industry’s leading provider of Customer Relationship Management (CRM) solutions. Designed specifically for Life Sciences, the company’s innovative business solutions incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Relationship Management enables more than 200,000 users in many of the world’s most innovative companies to stay ahead of market challenges. In addition to CRM, Cegedim Relationship Management also provides marketing, data optimization and regulatory compliance solutions in more than 80 countries. Cegedim Relationship Management is part of the France-based Cegedim S.A. Group.

To learn more, please visit: www.cegedim.com/rm.

About Cegedim: Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,500 people in more than 80 countries and generated revenue of €927 million in 2010. Cegedim SA is listed in Paris (EURONEXT: CGM).

To learn more, please visit: www.cegedim.com.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu Cegedim S.A.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Cegedim S.A.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Cegedim S.A. 10,75 1,42% Cegedim S.A.

Indizes in diesem Artikel